Insulin Costs Remain Top Target Beyond Biden’s Drug Price Cuts

A broad push by federal, state, and private sectors to lower insulin costs in the US is likely to persevere even as the Medicare drug price negotiation program faces legal resistance from the pharmaceutical industry.

Insulin’s cost has been at the top of federal and state government agendas as prices have risen alongside the number of Americans with diabetes. Over 37 million Americans have diabetes, according to the Centers for Disease Control and Prevention. And according to Yale, more than 7 million people need insulin daily.

One of the biggest moves to tackle insulin costs recently was from the Biden ...